Although COVID-19 has been somewhat controlled, it is still present in forms of different strains, which is why Pfizer, ...

On Thursday, Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $12.9 which represents a slight increase of $0.22 or 1.74% from the prior close of $12.68. The stock opened at $12.6 and ...

Novavax (NVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mayank Mamtani ...

This health news roundup covers various topics including Gerresheimer's stock jump due to an activist investor, a US list of ...

Novavax Inc (NVAX) reports significant revenue from Sanofi partnership and outlines strategic shifts to enhance future growth ...

Novavax, Inc. (NVAX) announced Wednesday that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025 ...

Novavax's vaccine is also authorized for use in the U.S., and is in line with guidance from the U.S. Food and Drug ...

The European Commission authorized Novavax's updated COVID-19 vaccine targeting the JN.1 strain of coronavirus in the region, ...

COVID-19 is a tricky virus, it changes and evolves all the time. So, as we learn in this story, we can’t let our guard down.

Shares of Novavax Inc. NVAX inched 0.15% higher to $13.04 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.45% ...

Shares of Novavax Inc. NVAX slid 4.34% to $13.02 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.18% to 17,923.90 ...

In terms of valuation, Novavax Inc’s market capitalization stands at $2.18 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value.